Cardiff Oncology is a San Diego biotechnology company developing onvansertib, an oral drug for several cancers. It last closed at $0.85 on Nov 17, down 0.15% on the day. The average 12-month price target from 2 analysts is $8.50 (+904.3% from the last close), with a high of $9.00 and a low of $8.00.
Only 2 firms rated CRDF in the past 90 days, not enough for a consensus
Average 12-month target
$8.50
▲ 904.3% upside
Based on 2 analysts who set a price target on CRDF in the past 90 days. The average target is $8.50, with a high of $9.00 and a low of $8.00, compared with the last close of $0.85.
Low $8.00Avg $8.50High $9.00
Blue marker: last close $0.85
Highest target$9.00
Average target$8.50
Lowest target$8.00
Latest rating changes
Craig-HallumInitiated
Sep 25Buy$2 → $8
HC Wainwright & Co.Upgrade
Sep 15Buy$9
Craig-HallumDowngrade
Jun 3Hold$2
Date
Firm
Action
Rating
Price target
Sep 25
Craig-Hallum
Initiated
Buy
$2 → $8
Sep 15
HC Wainwright & Co.
Upgrade
Buy
$9
Jun 3
Craig-Hallum
Downgrade
Hold
$2
Loading…
Technical Analysis
CRDF · as of the Nov 17 close · updated after every close
Downtrend
The stock sits between its 20 and 50 day averages. It is 58% below its 200 day average, so the longer trend is down. Momentum is neutral (RSI 47). The nearest support is the 20 day average at $0.84, and the nearest resistance the Pivot at $0.85.
Short trendBearish
Long trendBearish
MomentumNeutral
StretchNormal
VolatilityHigh, 9.3%/day
Key levels
$3.3152 week high+289.4%
$1.34200 day average+57.6%
$1.0350 day average+21.2%
$1.02100 day average+20.0%
$0.95Swing high (Oct 28)+11.8%
$0.91Pivot R1+7.1%
$0.85Pivot+0.0%
$0.85Last close
$0.8420 day average−1.2%
$0.79Pivot S1−7.1%
$0.78Swing low (Oct 27)−8.2%
$0.7152 week low−16.5%
Indicators
RSI (14)
46.53
Middle of its range
Neutral
MACD
-0.06
Above its signal line
Bullish
Stochastic
40.1
Middle of its range
Neutral
ADX (14)
31.3
Trending up
Williams %R
-43.3
Oversold below −80, overbought above −20
Neutral
CCI (20)
4.1
Oversold below −100, overbought above 100
Neutral
Rate of change
−1.9%
Change over 10 sessions
Bearish
ATR (14)
$0.08
Typical daily range, 9.3% of price
MA 10Above
MA 20Above
MA 50Below
MA 100Below
MA 200Below
Downtrend
Short trendBearish
Long trendBearish
MomentumNeutral
StretchNormal
VolatilityNormal, 23.9%/day
Key levels
$3.3152 week high+289.4%
$1.34200 day average+57.6%
$1.0350 day average+21.2%
$1.02100 day average+20.0%
$0.95Swing high (Oct 28)+11.8%
$0.91Pivot R1+7.1%
$0.85Pivot+0.0%
$0.85Last close
$0.8420 day average−1.2%
$0.79Pivot S1−7.1%
$0.78Swing low (Oct 27)−8.2%
$0.7152 week low−16.5%
Indicators
RSI (14)
39.29
Weak, oversold below 30
Neutral
MACD
-0.19
Below its signal line
Bearish
Stochastic
8.3
Near the bottom of its range
Oversold
ADX (14)
15.1
No clear trend
Williams %R
-83.0
Oversold below −80, overbought above −20
Oversold
CCI (20)
-71.8
Oversold below −100, overbought above 100
Neutral
Rate of change
−30.1%
Change over 10 sessions
Bearish
ATR (14)
$0.20
Typical daily range, 23.9% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for CRDF
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how CRDF did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
November seasonalityHow CRDF usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How CRDF has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2006.
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper trading
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether CRDF is in one of them and how their past CRDF trades turned out.
Cardiff Oncology is a biotechnology company based in San Diego, California, that develops cancer treatments. Its lead candidate, onvansertib, is an oral drug designed to block the PLK1 enzyme, and it is tested alone and alongside standard cancer therapies. The company is running studies in colorectal, pancreatic, lung, breast and blood cancers, focusing on patients whose tumors carry certain genetic markers.